晚期卵巢上皮癌腹腔化疗的预后意义  

The different prognostic significance of platinum-based intraperitoneal chemotherapy in advanced epithelial ovarian cancer

作　　者：臧荣余[1] 蔡树模[1] 张志毅[1] 翁练斌[1] 陈洁[1] 唐美琴[1] 

机构地区：[1]复旦大学医学院肿瘤医院肿瘤妇科,上海200032

出　　处：《实用肿瘤杂志》2001年第4期237-239,共3页Journal of Practical Oncology

摘　　要：目的　探讨腹腔化疗在晚期卵巢上皮癌 (AEOC)不同组别中 (残留灶≤ 1cm组、>1cm组 )的预后意义。方法　对 336例 AEOC患者以残癌大小作为分层因素进行腹腔化疗作用的回顾性分析 ,L og- rank检验生存率差异 ,Cox比例风险模型进行预后多因素分析。结果　残癌≤ 1cm组有无腹腔化疗的中位生存期分别为 46个月和36个月 ,差异有显著性 (P=0 .0 0 6 5 ,χ2 =7.39) ;残癌 >1cm组的生存期差异无显著性。多因素结果显示 ,腹腔化疗是 AEOC患者的预后影响因素之一。结论　腹腔化疗明显提高了残癌≤ 1cm组的远期生存期 ,该结果有待于随机化研究证实。Objective To investigate the role of first-line intraperitoneal chemotherapy in the management of advanced epithelial ov arian cancer (AEOC).Methods From 1986 to 1997,336 patients with stage Ⅲ and stage Ⅳ ovarian cancer treated in our institute were retrospectiv ely reviewed, and the patients were divided into optimal and suboptimal groups a ccording to the residual disease after primary surgical cytoreduction.Re sults In the optimal group, there was a significant difference in survi val between patients with and without intraperitoneal chemotherapy, with an esti mated median survival of 46 months and 36 months,respectively ( P =0.0065, χ2 =7.39). Intraperitoneal chemotherapy was also identified as one of indepe ndent prognostic factors of survival by Cox stepwise regression analysis.Conclusion Intraperitoneal chemotherapy can significantly improve lon g-term survival of patients with optimal advanced epithelial ovarian cancer.

关 键 词：卵巢肿瘤 腹腔化疗 预后 存活率 卵巢上皮癌 AEOC 

分 类 号：R737.31[医药卫生—肿瘤]